Abstract Library

#4562 Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,

#4121 The efficacy and safety analysis of transarterial embolisation in the treatment of cystic neuroendocrine neoplasm liver metastasis

Introduction: Liver metastases are common in neuroendocrine neoplasm (NEN). Cystic NEN liver metastases (cNENLM) are rare, and the efficacy of transarterial embolization (TAE) has not been reported.

Conference:

Presenting Author:

Authors: Yu H, Wang Y, Zhang N, Liu H, Chen L,

Keywords: Transaterial embolization, Neuroendocrine neoplasm, Liver metastasis, Cystic, Efficacy, Safety,

#3633 Tumor mutation burden in gastroenteropancreatic neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are rare tumors with limited treatment options. Microsatellite instability (MSI) and tumor mutation burden (TMB) are novel biomarkers in various tumor types. However, few studies have been performed for these novel biomarkers in gastroenteropancreatic (GEP)- NENs.

Conference:

Presenting Author: Sun Young J

Authors: Sun Young J, Seung Tae K, Young Suk P, Jeeyun L,

Keywords: tumor mutation burden, neuroendocrine tumor, neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine neoplasm,

#3181 Clinical features of 8 cases of neuroendocrine tumor with multi-hormone secretion

Introduction: A group of patients with functional neuroendocrine tumors (NET) may suffer from syndrome caused by multi-hormone secretion.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Guo Y

Authors: Guo Y, Chen L, Liu M, Zhang Y, Zhang Y,

Keywords: neuroendocrine tumor, multi-hormone secretion,